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RNA与 Cas 相关蛋白识别特异 DNA序列并对其进行切割。与传统基因编辑工具如




因此，我们利用来源于上海生科院的 pCas和 pTarget 质粒来表达 CRISPR-Cas9





已有的双质粒系统进行改造，构建新的 IPTG 诱导 sgRNA表达的单质粒系统。观察





敏感性，最大效率可以达到 106倍。最后，为了进一步缩短使用 CRISPR 系统时的











































The discovery of antibiotic is the great milestone for fighting against the bacterial 
infection. However, the traditional antibiotic works by blocking conserved bacterial 
signaling or metabolic pathways, therefore it is unable to distinguish between the 
pathogen needed to be killed and the bacteria being good for us, Long-termed usage will 
lead to dysbacteriosis and drug-resistance. We need to find new antibacterial drugs that 
can target pathogens or drug-resistant bacteria specifically. CRISPR-Cas9 system is 
originated from bacterial adaptive immunity, which utilize the RNA and Cas-related 
protein to recognize the special DNA sequence and cut it. Compared with the traditional 
gene editing tools such as ZFNs and TALENs, it is more simple and effective. Thus 
CRISPR-Cas9 system, as a new gene editing tool, is applied in many fields for gene 
knock out, knock in or point mutant. On the other hand, researchers make use of it ability 
to recognizing gene sequence specially to distinguish pathogen or drug-resistant bacteria 
from normal bacterial flora in genetic level and to selectively eliminate pathogen and 
drug-resisant mutant. 
  We utilized pCas and pTargetF, obtained from Shanghai Research Center of Industrial 
Biotechnology to expressed CRISPR-Cas9 system and successfully performed single gene 
(ftnA) deletion, simultaneous two-gene (ftnA and ftnB) deletion, and single base point 
mutantion (in the kdpD gene) in E.coli genome. ftnA and ftnB encode iron storage related 
protein in E.coli genome. The efficiency for gene editing is almost 100% in the strains we 
test. For the purpose of eliminating drug-resistant bacteria, we constructed drug-resistant 
plasmids containing genes encoding carbapenemase, which confers resistance to 
-lactams, and transformed it into WT (BW25113) to form drug-resistant bacteria. And 
then we designed N20-sgRNA targeting drug-resistant genes to clear drug-resistant 
bacteria specifically. Then, we reconstructed the two plasmid system into one plasmid 
system that only contains a new pCas-m plasmid to experss sgRNA under IPTP induced 
promoter. We used the new IPTG-induced system to observe the kinetic changes of 
clearing efficiency of drug-resistant genes. In order to improve the resistant gene 
















recognition and cut sites in the plasmid or using recombination repair-deficient strain. In 
order to expand the drug-resistant gene range that the CRISPR system could target, we 
tried to cleave clinically-isolated colistin-resistant plasmid. The result showed that we can 
eliminate drug-resistant plasmid containing target region specifically and resensitize 
bacteria to antibiotic. The maximal resistant gene removel efficiency can be as high as 6 
orders of magnitude. Finally, in order to shorten the step and time when using CRISPR 
system, we tried to rebuild cloning-free CRISPR by using T7-promoter transcriptional 
system to simplify the plasmid construct process. We showed that the T7-promoter 
transcriptional system allow CRISPR system to function, but the result is not ideal 
because the segment sgRNA is not stable in the cell. So we need more ways to improve 
the stability of DNA fragment to achieve cloning-free’s aim. 
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H/h/hr Hour 小时 
min Minute 分钟 
Sec/s Second 秒 
Amp Ampicilin 氨苄青霉素 
Car Carbenicillin 羧苄青霉素 
Mer Meropenem 美罗培南 
Kan Kanamycin 卡那霉素 
Spec Spectinomycin 大观霉素 
Cm Chloramphenicol 氯霉素 
Bp Base pair 碱基对 
ml Milliliter 毫升 
L Liter 升 
U Unit 单位 
IPTG Isopropyl-β-d-thiogalactoside 异丙基-β-d-硫代半乳糖
酶 
PCR Polymerase chain reaction 聚合酶链式反应 
OD Optical density 光密度 
rpm Rotations per minute 转/分 
EB Ethidium bromide 溴化乙锭 
MIC Minimum  Inhibitory 
Concentration 
最小抑菌浓度 
DSB  Double stands break 双链断裂 
HR  Homologous recombination 同源重组修复 






















1.1 基因编辑与 CRISPR-Cas9系统 
1.1.1 传统基因编辑技术 











 通过对细菌和酵母的 DNA 修复路径的研究表明，当 DNA 链上发生双链断裂
(DSB double stands break) 时会极大的激活细胞中的修复重组系统即同源重组修复
系统 (HR homologous recombination) 和非同源重组修复系统 (NHEJ error-prone 
nonhomologous end joining) 对断裂的 DNA链进行修复[3-4]。因此，研究人员尝试利
用位点特异性内切酶对目标基因切割并且通过引入不同的修复模板从而完成对基因
的一系列编辑来研究基因的功能。由此引申而出的传统的基因编辑工具包括锌指核
酸内切酶 (ZFNs zinc finger nucleases) 与类转录激活因子效应物核酸酶 (TALENs 
transcription activator-like effector nucleases)。他们都是将能识别特异序列的蛋白质与
具有非特异性核酸内切酶活性的 FokⅠ融合，识别特异基因序列并进行切割，并通
过引入不同的修复模板从而达到对基因编辑的目的。 
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